Tag: CSL

post-image

Australia’s biggest R&D companies revealed

Atlassian, CSL and Cochlear are the biggest users of Australia’s research and development tax incentive, with the software giant alone claiming more than $200 million of activity a year,...

MTPConnect secures $28.5m for MedTech accelerator

Posted on   |  by Brandon How
A $28.5 million commercialisation boost will soon be available to MedTechs fighting heart disease and diabetes under the latest round of a Medical Research Future Fund program. The second...

$65m biotech incubator names first 16 residents

Posted on   |  by Justin Hendry
A wearable “lab-on-a-chip” solution for hormone monitoring, a gum disease vaccine and technology for creating 3D models of human brain tissue are among the ideas that have piqued the...

Govt opens consultation on capitalising on RNA capability

Posted on   |  by Joseph Brookes
The federal government is considering further support for parts of the RNA sector after helping establish the southern hemisphere’s first commercial mRNA manufacturing capability in Melbourne. The Industry department...

CSL-backed biotech startup incubator launches

Posted on   |  by Justin Hendry
A new biotech incubator backed by $65 million in industry and government investment has launched, offering innovative Australian startups access to a wet lab space and other facilities in...

CSL profit, revenue up 10%, but share price falls

Posted on   |  by Peter Roberts
There seems to be no pleasing demanding shareholders with biotechnology giant CSL punished by the market despite announcing a greater than ten per cent rise in both revenues and...

Academy calls for manufacturing boost for vaccines

Posted on   |  by James Riley
Without the ability to produce vaccines onshore, Australia and the region remain vulnerable to supply shocks and ‘vaccine nationalism’, the Academy of Science says in a pre-budget submission to...

Vaccine maker CSL’s massive year, massive profits

Posted on   |  by Peter Roberts
Australia’s largest company by market capitalisation, biotechnology manufacturer CSL has powered ahead in the first half of the financial year reporting a net profit after tax up 44 per...

The Pivot: Lessons from the biotech frontline

Posted on   |  by Ian Nisbet
“If plan A doesn’t work, the alphabet has 25 more letters – 46 if you’re in Japan.” (Claire Cook, Seven Year Switch) In the late 1980s and early 1990s...